Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo

Who May Qualify: - Patient ≥ 18 years old - SOFA score for first 24 hours post-admission ≥ 6 - Mechanically ventilated at the time of inclusion (non-invasive ventilation (NIV) and high-flow nasal oxygen excluded) - mHLA-DR\< 8,000 AB/C measured between the 5th and 10th day after admission to the intensive care unit - Patient affiliated to a social security scheme - Written consent (relative/trusted person) Who Should NOT Join This Trial: - Patient with estimated life expectancy of less than 3 months - Patients with a predicted remaining stay in intensive care \< 72 hours - Patient with pre-existing immunosuppression: solid cancer active or in remission for \< 5 years, active hemopathy or in remission for \< 5 years, systemic disease (including in the absence of specific treatment), solid organ transplant or marrow allograft patient, patient suffering from a HIV infection - Patients with an expected prolonged duration of mechanical ventilation: comatose or vegetative patients (admission for severe stroke with Glasgow score \< 8, patient resuscitated from an arterial stroke,) patients with tracheotomy for ENT problems, patients suffering from muscular disease (e.g. myopathy), patients on long-term mechanical ventilation - Pregnant or breast-feeding women - Contraindication of Imukin (hypersensitivity to interferon gamma-1b or known hypersensitivity to related products, such as another interferon) - Patients on immunosuppressive therapy, including long-term corticosteroid therapy (\>2.5mg/d prednisone equivalent) - Patients with severe hepatic or renal insufficiency - Patient included in another interventional clinical trial - People under court protection and protected adults Always talk to your doctor about whether this trial is right for you.